Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer United States Mexico

Hi-Tech Hunts Growth As FTC Picks Up Scent On Disputed Weight Loss Claims

This article was originally published in The Tan Sheet

  • News

Executive Summary

FTC asks a federal court to re-instate a contempt order stemming from Hi-Tech Pharmaceuticals’ misleading claims for weight loss supplements that an appellate court overturned. Hi-Tech, meanwhile, argues for recusal of the judge who found the firm in contempt and ordered two executives to jail.

You may also be interested in...



Hi-Tech CEO Wheat Arrested In FDA Investigation Of Steroid-Spiked Supplements

Hi-Tech Pharmaceuticals CEO Jared Wheat and an associate face 18 criminal charges in federal court alleging they falsified FDA documents and distributed as supplements products containing steroid ingredient. Wheat is appealing the indictment to federal circuit court.

Hi-Tech Avoids FTC Contempt Charge, But Not The Judge

Judge Charles Parnell rejects FTC’s motion for a summary judgment against Hi-Tech of contempt of a 2008 settlement, and also rejects the firm’s recusal motion.

Hi-Tech Avoids FTC Contempt Charge, But Not The Judge

Judge Charles Parnell rejects FTC’s motion for a summary judgment against Hi-Tech of contempt of a 2008 settlement, and also rejects the firm’s recusal motion.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Consumer United States Mexico
Latest Headlines

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

See All
UsernamePublicRestriction

Register

PS107868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By